Orexo AB publ

Orexo AB publ is a Swedish pharmaceutical company founded in 1995 with a mission to improve the lives of patients suffering from mental illness and substance use disorder. With over 25 years of experience, Orexo has developed improved pharmaceuticals based on proprietary formulation technologies, addressing significant medical needs. The company focuses on providing innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases in the US market and collaborates with leading partners to develop and commercialize products targeting other therapeutic areas worldwide. Orexo's total net sales in 2022 amounted to SEK 624 million, with 126 employees and is listed on Nasdaq Stockholm's main list, while also available as an ADR on OTCQX (ORXOY) in the US. In March 2024, Orexo secured a kr500.00MPost-IPO Debt investment. The company's dedication to addressing critical health challenges and its successful track record in the pharmaceutical industry make it an attractive opportunity for investors seeking to contribute to the advancement of healthcare solutions. Orexo's commitment to driving positive outcomes for patients aligns with the growing focus on mental health and addiction treatment, positioning the company for potential growth and impact in the healthcare sector. Investors looking to support innovative pharmaceutical solutions and address unmet medical needs may find Orexo to be a compelling investment opportunity. For more information about Orexo, please visit its website: www.orexo.com.